Mergers & Acquisitions in Pharma — What 2025 taught us and where the momentum is heading in 2026
2025 almost felt like pharma pressed a reset button on dealmaking. Money moved in patches, a handful of blockbuster deals grabbed headlines and reshaped competitive positions, while the broader market kept its cautionary posture. If you follow the industry, two impressions stand out: (1) big strategic buys kept happening, often to buy pipeline or platform breadth, and (2) dealmakers got picky, structuring transactions with milestones, royalties, and shared-risk components instead of all-cash rollups. Below, we break down the most consequential moves of 2025, why they matter, and what 2026 is shaping up to become: The headline deals and why they mattered A few deals dominated the news cycle and importantly, will influence strategic behavior for years. Johnson & Johnson → Intra-Cellular Therapies (~$14.6B) J&J’s acquisition of Intra-Cellular was one of the largest pharma deals of the year, signaling continued interest in CNS and specialty assets that can expand a big co...